aluates Reports

$ 0.0

Automative

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Research Report 2026

Published Date: 2026-01-20

Report Code: QYRE-Auto-3D18901

Global Mesenchymal Stem Cell MSCs Therapeutic Product CDMO Service Market Research Report 2024

BUY CHAPTERS

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Research Report 2026

Code: QYRE-Auto-3D18901

Report

2026-01-20

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Lonza

Thermo Fisher

Creative-Biolabs

Reprocell

ATCC

Beijing CytoNiche Biotech

OmniaBio

Histocell S.L.

FUJIFILM Diosynth Biotechnologies

ENCELL

Mycenax

uBriGene Biosciences International

Taiwan Bio Therapeutics

Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size

The global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market was valued at US$ 553 million in 2025 and is anticipated to reach US$ 1087890 million by 2032, at a CAGR of 198.4% from 2026 to 2032.

Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.

The North American market for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service in Large Pharmaceutical Company is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service include Lonza, uBriGene Biosciences International, Thermo Fisher, Creative Biolabs, REPROCELL, ATCC, Beijing CytoNiche Biotech, OmniaBio, Histocell, FUJIFILM Diosynth Biotechnologies, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service. The Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Report

Report Metric	Details
Report Name	Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market
Accounted market size in 2025	US$ 553 million
Forecasted market size in 2032	US$ 1087890 million
CAGR	198.4%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Cell Therapy Cell-derived Products
Segment by Application	Large Pharmaceutical Company Small and Medium-sized Pharmaceutical Company
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, uBriGene Biosciences International, Thermo Fisher, Creative Biolabs, REPROCELL, ATCC, Beijing CytoNiche Biotech, OmniaBio, Histocell, FUJIFILM Diosynth Biotechnologies, Taiwan Bio Therapeutics, Encell Co., Ltd., Mycenax
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market growing?

Ans: The Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market witnessing a CAGR of 198.4% during the forecast period 2026-2032.

What is the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market size in 2032?

Ans: The Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market size in 2032 will be US$ 1087890 million.

Who are the main players in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market report?

Ans: The main players in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market are Lonza, uBriGene Biosciences International, Thermo Fisher, Creative Biolabs, REPROCELL, ATCC, Beijing CytoNiche Biotech, OmniaBio, Histocell, FUJIFILM Diosynth Biotechnologies, Taiwan Bio Therapeutics, Encell Co., Ltd., Mycenax

What are the Application segmentation covered in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market report?

Ans: The Applications covered in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market report are Large Pharmaceutical Company, Small and Medium-sized Pharmaceutical Company

What are the Type segmentation covered in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market report?

Ans: The Types covered in the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market report are Cell Therapy, Cell-derived Products

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Cell Therapy

1.2.3 Cell-derived Products

1.3 Market by Application

1.3.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Large Pharmaceutical Company

1.3.3 Small and Medium-sized Pharmaceutical Company

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Perspective (2021–2032)

2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Growth Trends by Region

2.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Region (2021–2026)

2.2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (2027–2032)

2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Dynamics

2.3.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industry Trends

2.3.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers

2.3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges

2.3.4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue

3.1.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue (2021–2026)

3.1.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Players (2021–2026)

3.2 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue

3.4 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio

3.4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2025

3.5 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Head Offices and Areas Served

3.6 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Products and Applications

3.7 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Type

4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Type (2021–2026)

4.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (2027–2032)

5 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Application

5.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Application (2021–2026)

5.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2021–2032)

6.2 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2021–2026)

6.4 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2021–2032)

7.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2021–2026)

7.4 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2021–2032)

8.2 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2021–2026)

8.4 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2021–2032)

9.2 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2021–2026)

9.4 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2021–2032)

10.2 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2021–2026)

10.4 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.1.4 Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.1.5 Lonza Recent Development

11.2 uBriGene Biosciences International

11.2.1 uBriGene Biosciences International Company Details

11.2.2 uBriGene Biosciences International Business Overview

11.2.3 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.2.4 uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.2.5 uBriGene Biosciences International Recent Development

11.3 Thermo Fisher

11.3.1 Thermo Fisher Company Details

11.3.2 Thermo Fisher Business Overview

11.3.3 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.3.4 Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.3.5 Thermo Fisher Recent Development

11.4 Creative Biolabs

11.4.1 Creative Biolabs Company Details

11.4.2 Creative Biolabs Business Overview

11.4.3 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.4.4 Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.4.5 Creative Biolabs Recent Development

11.5 REPROCELL

11.5.1 REPROCELL Company Details

11.5.2 REPROCELL Business Overview

11.5.3 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.5.4 REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.5.5 REPROCELL Recent Development

11.6 ATCC

11.6.1 ATCC Company Details

11.6.2 ATCC Business Overview

11.6.3 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.6.4 ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.6.5 ATCC Recent Development

11.7 Beijing CytoNiche Biotech

11.7.1 Beijing CytoNiche Biotech Company Details

11.7.2 Beijing CytoNiche Biotech Business Overview

11.7.3 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.7.4 Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.7.5 Beijing CytoNiche Biotech Recent Development

11.8 OmniaBio

11.8.1 OmniaBio Company Details

11.8.2 OmniaBio Business Overview

11.8.3 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.8.4 OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.8.5 OmniaBio Recent Development

11.9 Histocell

11.9.1 Histocell Company Details

11.9.2 Histocell Business Overview

11.9.3 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.9.4 Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.9.5 Histocell Recent Development

11.10 FUJIFILM Diosynth Biotechnologies

11.10.1 FUJIFILM Diosynth Biotechnologies Company Details

11.10.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.10.3 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.10.4 FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.10.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.11 Taiwan Bio Therapeutics

11.11.1 Taiwan Bio Therapeutics Company Details

11.11.2 Taiwan Bio Therapeutics Business Overview

11.11.3 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.11.4 Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.11.5 Taiwan Bio Therapeutics Recent Development

11.12 Encell Co., Ltd.

11.12.1 Encell Co., Ltd. Company Details

11.12.2 Encell Co., Ltd. Business Overview

11.12.3 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.12.4 Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.12.5 Encell Co., Ltd. Recent Development

11.13 Mycenax

11.13.1 Mycenax Company Details

11.13.2 Mycenax Business Overview

11.13.3 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction

11.13.4 Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

11.13.5 Mycenax Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lonza

Thermo Fisher

Creative-Biolabs

Reprocell

ATCC

Beijing CytoNiche Biotech

OmniaBio

Histocell S.L.

FUJIFILM Diosynth Biotechnologies

ENCELL

Mycenax

uBriGene Biosciences International

Taiwan Bio Therapeutics

List of Tables

Table 1. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Cell Therapy

Table 3. Key Players of Cell-derived Products

Table 4. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 5. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million), 2021–2026

Table 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2021–2026)

Table 8. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (US$ Million), 2027–2032

Table 9. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2027–2032)

Table 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends

Table 11. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers

Table 12. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges

Table 13. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints

Table 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue by Players (US$ Million), 2021–2026

Table 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players (2021–2026)

Table 16. Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Tier (Tier 1, Tier 2, and Tier 3), based on Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, 2025

Table 17. Ranking of Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Companies by Revenue (US$ Million) in 2025

Table 18. Global 5 Largest Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (CR5 and HHI), 2021–2026

Table 19. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Headquarters and Area Served

Table 20. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Products and Applications

Table 21. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of General Availability (GA)

Table 22. Mergers and Acquisitions, Expansion Plans

Table 23. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Type (US$ Million), 2021–2026

Table 24. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2021–2026)

Table 25. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (US$ Million), 2027–2032

Table 26. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2027–2032)

Table 27. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (US$ Million), 2021–2026

Table 28. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2021–2026)

Table 29. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (US$ Million), 2027–2032

Table 30. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2027–2032)

Table 31. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 32. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 33. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 34. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 36. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 37. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 38. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million), 2021–2026

Table 39. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million), 2027–2032

Table 40. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 41. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 42. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 43. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 45. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 46. Lonza Company Details

Table 47. Lonza Business Overview

Table 48. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 49. Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 50. Lonza Recent Development

Table 51. uBriGene Biosciences International Company Details

Table 52. uBriGene Biosciences International Business Overview

Table 53. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 54. uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 55. uBriGene Biosciences International Recent Development

Table 56. Thermo Fisher Company Details

Table 57. Thermo Fisher Business Overview

Table 58. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 59. Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 60. Thermo Fisher Recent Development

Table 61. Creative Biolabs Company Details

Table 62. Creative Biolabs Business Overview

Table 63. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 64. Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 65. Creative Biolabs Recent Development

Table 66. REPROCELL Company Details

Table 67. REPROCELL Business Overview

Table 68. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 69. REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 70. REPROCELL Recent Development

Table 71. ATCC Company Details

Table 72. ATCC Business Overview

Table 73. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 74. ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 75. ATCC Recent Development

Table 76. Beijing CytoNiche Biotech Company Details

Table 77. Beijing CytoNiche Biotech Business Overview

Table 78. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 79. Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 80. Beijing CytoNiche Biotech Recent Development

Table 81. OmniaBio Company Details

Table 82. OmniaBio Business Overview

Table 83. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 84. OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 85. OmniaBio Recent Development

Table 86. Histocell Company Details

Table 87. Histocell Business Overview

Table 88. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 89. Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 90. Histocell Recent Development

Table 91. FUJIFILM Diosynth Biotechnologies Company Details

Table 92. FUJIFILM Diosynth Biotechnologies Business Overview

Table 93. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 94. FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 95. FUJIFILM Diosynth Biotechnologies Recent Development

Table 96. Taiwan Bio Therapeutics Company Details

Table 97. Taiwan Bio Therapeutics Business Overview

Table 98. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 99. Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 100. Taiwan Bio Therapeutics Recent Development

Table 101. Encell Co., Ltd. Company Details

Table 102. Encell Co., Ltd. Business Overview

Table 103. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 104. Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 105. Encell Co., Ltd. Recent Development

Table 106. Mycenax Company Details

Table 107. Mycenax Business Overview

Table 108. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product

Table 109. Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (US$ Million), 2021–2026

Table 110. Mycenax Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

Table 114. Authors List of This Report

List of Figures

Figure 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Picture

Figure 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Type: 2025 vs 2032

Figure 4. Cell Therapy Features

Figure 5. Cell-derived Products Features

Figure 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (US$ Million), 2021–2032

Figure 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Application: 2025 vs 2032

Figure 8. Large Pharmaceutical Company Case Studies

Figure 9. Small and Medium-sized Pharmaceutical Company Case Studies

Figure 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Report Years Considered

Figure 11. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 12. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 13. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region: 2025 vs 2032

Figure 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players in 2025

Figure 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 16. The Top 10 and 5 Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2025

Figure 17. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 18. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2021–2032)

Figure 19. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. Canada Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2021–2032)

Figure 23. Germany Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. France Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. U.K. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Italy Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Russia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Ireland Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2021–2032)

Figure 31. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Australia & New Zealand Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2021–2032)

Figure 39. Mexico Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Brazil Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2021–2032)

Figure 43. Israel Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Saudi Arabia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. UAE Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Lonza Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 47. uBriGene Biosciences International Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 48. Thermo Fisher Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 49. Creative Biolabs Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 50. REPROCELL Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 51. ATCC Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 52. Beijing CytoNiche Biotech Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 53. OmniaBio Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 54. Histocell Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 55. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 56. Taiwan Bio Therapeutics Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 57. Encell Co., Ltd. Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 58. Mycenax Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2021–2026)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License